- Home
- ELVN vs XPEL Comparison
ELVN vs XPEL Comparison
Compare ELVN & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- XPEL
- Stock Information
- Founded
- ELVN 2016
- XPEL 1999
- Country
- ELVN United States
- XPEL United States
- Employees
- ELVN N/A
- XPEL N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- ELVN Health Care
- XPEL Industrials
- Exchange
- ELVN Nasdaq
- XPEL Nasdaq
- Market Cap
- ELVN 1.1B
- XPEL 1.2B
- IPO Year
- ELVN 2020
- XPEL N/A
- Fundamental
- Price
- ELVN $21.00
- XPEL $30.80
- Analyst Decision
- ELVN Strong Buy
- XPEL Buy
- Analyst Count
- ELVN 5
- XPEL 2
- Target Price
- ELVN $37.80
- XPEL $49.00
- AVG Volume (30 Days)
- ELVN 213.5K
- XPEL 241.5K
- Earning Date
- ELVN 03-17-2025
- XPEL 05-01-2025
- Dividend Yield
- ELVN N/A
- XPEL N/A
- EPS Growth
- ELVN N/A
- XPEL N/A
- EPS
- ELVN N/A
- XPEL 1.65
- Revenue
- ELVN N/A
- XPEL $420,400,000.00
- Revenue This Year
- ELVN N/A
- XPEL $16.12
- Revenue Next Year
- ELVN N/A
- XPEL $16.49
- P/E Ratio
- ELVN N/A
- XPEL $18.71
- Revenue Growth
- ELVN N/A
- XPEL 6.08
- 52 Week Low
- ELVN $10.90
- XPEL $29.00
- 52 Week High
- ELVN $30.03
- XPEL $60.49
- Technical
- Relative Strength Index (RSI)
- ELVN 47.82
- XPEL 27.66
- Support Level
- ELVN $18.67
- XPEL $29.00
- Resistance Level
- ELVN $22.36
- XPEL $41.59
- Average True Range (ATR)
- ELVN 1.07
- XPEL 1.79
- MACD
- ELVN 0.06
- XPEL -0.98
- Stochastic Oscillator
- ELVN 60.84
- XPEL 12.33
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About XPEL XPEL Inc.
XPEL Inc is a provider of protective films and coatings, including automotive paint protection film, surface protection film, automotive and commercial/residential window films, and ceramic coatings. The company has a network of trained installers and proprietary DAP software, dedicated to exceeding customer expectations by providing quality products, customer service, technical support, and world-class training. The majority of revenue is derived from the United states.